NEW YORK, Oct. 18 – Incyte Genomics and Medarex said Thursday they would work together to develop and commercialize human antibody therapeutics.

Under the terms of the deal, Medarex and Incyte will share the preclinical and clinical development costs associated with developing antibody products. The two companies said they would also jointly sell and distribute products resulting from the collaboration.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.